860 results on '"Van Vollenhoven, R"'
Search Results
2. POS0544 BELIMUMAB INCREASES SRI-4 RESPONSE RATES VERSUS PLACEBO IN EARLY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: A LARGE INTEGRATED ANALYSIS OF BELIMUMAB TRIALS
3. AB0775 NOVEL THERAPEUTICS TO PREVENT RHEUMATOID ARTHRITIS DEVELOPMENT IN AT-RISK INDIVIDUALS, UNCOVERED BY IN SILICO DRUG REPURPOSING
4. POS0549 OUTCOMES OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS TREATED WITH INTRAVENOUS OR SUBCUTANEOUS BELIMUMAB: A POST-HOC EFFICACY META-ANALYSIS BY BICLA CRITERIA
5. POS0474 ULTRASOUND REMISSION RATES AFTER 1 YEAR ARE HIGH IN EARLY RA PATIENTS ON INDUCTION TREATMENT: RESULTS FROM THE RANDOMIZED NORD-STAR TRIAL
6. POS0528 LUPUS LOW DISEASE ACTIVITY STATE ATTAINMENT AND REDUCED GLUCOCORTICOID USE IN PATIENTS WITH SLE IN THE TULIP LONG-TERM EXTENSION TRIAL OF ANIFROLUMAB
7. POS0543 KINETICS OF MUCOCUTANEOUS AND MUSCULOSKELETAL RESPONSES TO DEUCRAVACITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IN THE PHASE 2 PAISLEY TRIAL
8. AB0758 CIRCULATING ADIPOKINES AND RESPONSE TO TREATMENT IN EARLY RHEUMATOID ARTHRITIS – DATA FROM THE RANDOMIZED NORD-STAR TRIAL
9. AB0982 DOMAINS FOR INCLUSION IN A NOVEL TREATMENT RESPONSE MEASURE FOR SYSTEMIC LUPUS ERYTHEMATOSUS (TRM-SLE): RESULTS OF A MODIFIED DELPHI STUDY
10. POS0530 BELIMUMAB REDUCES DISEASE FLARES VERSUS PLACEBO IN ADULTS WITH EARLY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF A LARGE INTEGRATED ANALYSIS
11. OP0053 THE EFFECTS OF RITUXIMAB ON QUALITY OF LIFE, PAIN AND MOBILITY SCORES IN THE PRECLINICAL PHASE OF RHEUMATOID ARTHRITIS: 2 YEAR DATA FROM THE PRAIRI STUDY
12. Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort
13. Profil de tolérance de l’upadacitinib chez des patients atteints de polyarthrite rhumatoïde après une durée d’exposition pouvant aller jusqu’à 6,5 ans
14. Neutrophil activation identifies patients with active polyarticular gout
15. Blood chemokine levels are markers of disease activity but not predictors of remission in early rheumatoid arthritis
16. POS0324 OBESITY IS A RISK FACTOR FOR POOR RESPONSE TO TREATMENT IN EARLY RHEUMATOID ARTHRITIS - A NORD-STAR SPIN-OFF STUDY
17. POS0826 SAFETY PROFILE OF UPADACITINIB UP TO 6.5 YEARS OF EXPOSURE IN PATIENTS WITH RHEUMATOID ARTHRITIS
18. POS0632 TARGETING NET FORMATION IN EARLY RA PATIENTS; A SPIN-OFF STUDY FROM THE NORD-STAR
19. POS1036 NF-ΚB SIGNALLING IS CRITICALLY IMPORTANT FOR FUNCTIONAL RESPONSES OF ACPA-PRODUCING B CELL CLONES FROM PATIENTS WITH RHEUMATOID ARTHRITIS
20. OP0137 EFFICACY AND SAFETY OF TELITACICEPT, A NOVEL BLYS/APRIL DUAL INHIBITOR, IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED 52-WEEK STUDY
21. AB0530 DESIGN OF 2 PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, GLOBAL TRIALS OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 (TYK2) INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS
22. OP0051 LUPUS LOW DISEASE ACTIVITY STATE ATTAINMENT IN THE PHASE 3 PLACEBO-CONTROLLED TULIP LONG-TERM EXTENSION TRIAL OF ANIFROLUMAB
23. POS1153 APPLYING THE WORKING DEFINITION OF THE DISEASE MODIFICATION CRITERIA TO SYSTEMIC LUPUS ERYTHEMATOSUS TREATMENTS FROM THE PUBLISHED LITERATURE
24. OP0142 EFFICACY AND SAFETY OF TELITACICEPT, A NOVEL BLYS/APRIL DUAL INHIBITOR, IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME: A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED 24-WEEK STUDY
25. POS0322 CLINICAL DISEASE ACTIVITY INDEX REMISSION IN RHEUMATOID ARTHRITIS AT 6 MONTHS IS ASSOCIATED WITH HIGHER FREQUENCY OF TRANSITIONAL B CELLS AT DIAGNOSIS
26. POS0249 SEX DIFFERENCES IN PATIENT-REPORTED OUTCOMES IN AXIAL SPONDYLOARTHRITIS PATIENTS TREATED WITH TUMOR NECROSIS FACTOR INHIBITORS: RESULTS FROM A MULTINATIONAL OBSERVATIONAL COHORT STUDY
27. IgG4:IgG RNA ratio differentiates active disease from remission in granulomatosis with polyangiitis: a new disease activity marker? A cross-sectional and longitudinal study
28. Gender Differences in Axial Spondyloarthritis: Women Are Not So Lucky
29. S11.2 Efficacy and safety of deucravacitinib, a selective TYK2 inhibitor, in patients with active systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study
30. PO.1.22 Online education significantly improved rheumatologists’ knowledge and confidence in minimizing long-term organ damage in SLE
31. PO.8.186 SLE-T2T – a digital treat-to-target clinical decision support system for the management of systemic lupus erythematosus patients: development and usability evaluation
32. CERTOLIZUMAB-PEGOL, ABATACEPT, TOCILIZUMAB OR ACTIVE CONVENTIONALTHERAPY IN EARLY RHEUMATOID ARTHRITIS: CLINICAL AND RADIOGRAPHIC 48-WEEKS RESULTS OF THE INVESTIGATOR-INITIATED RANDOMIZED NORD-STARTRIAL
33. SEX DIFFERENCES IN EFFECTIVENESS OF FIRST-LINE TUMOR NECROSIS FACTOR INHIBITORS IN AXIAL SPONDYLOARTHRITIS; RESULTS FROM FIFTEEN COUNTRIES IN THE EUROSPA RESEARCH COLLABORATION NETWORK
34. Efficacité et tolérance du traitement séquentiel belimumab (BEL) sous-cutané et rituximab (RTX) chez des patients atteints de lupus systémique (LS) : étude BLISS-BELIEVE de phase 3, randomisée, contrôlée versus placebo
35. Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study
36. OP0058 CERTOLIZUMAB-PEGOL, ABATACEPT, TOCILIZUMAB OR ACTIVE CONVENTIONAL THERAPY IN EARLY RHEUMATOID ARTHRITIS: CLINICAL AND RADIOGRAPHIC 48-WEEKS RESULTS OF THE INVESTIGATOR-INITIATED RANDOMIZED NORD-STAR TRIAL
37. POS0709 SUSTAINED BICLA AND BILAG ORGAN DOMAIN RESPONSES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) RECEIVING ANIFROLUMAB IN TWO PHASE 3 TRIALS
38. POS0190 EFFICACY AND SAFETY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM TWO RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDIES
39. POS0516 PLASMA CALPROTECTIN WAS ASSESSED IN MULTIPLE BIOLOGICAL TREATMENT STRATEGIES FOR EARLY RHEUMATOID ARTHRITIS
40. OP0059 PROFOUND ANTICOAGULANT EFFECTS OF INITIAL ANTIRHEUMATIC TREATMENTS IN EARLY RHEUMATOID ARTHRITIS PATIENTS: A NORD-STAR SPIN-OFF STUDY
41. AB0333 SUSTAINABILITY OF RESPONSE TO UPADACITINIB AMONG PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS REFRACTORY TO BIOLOGICAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
42. POS0184 EFFICACY OF BIIB059 ON SKIN MANIFESTATIONS IN PARTICIPANTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IN THE PHASE 2 LILAC STUDY (PART A)
43. OP0178 COVID-19 BREAKTHROUGH INFECTIONS IN VACCINATED PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES AND CONTROLS – DATA FROM TWO PROSPECTIVE COHORT STUDIES
44. POS1408 AN ULTRASOUND NEGATIVE FOR SUBCLINICAL SYNOVITIS IN PATIENTS WITH ARTHRALGIA: IS IT HELPFUL IN IDENTIFYING THOSE WHO WILL NOT DEVELOP INFLAMMATORY ARTHRITIS? A LONGITUDINAL STUDY IN FOUR ARTHRALGIA COHORTS
45. OP0020 SEX DIFFERENCES IN EFFECTIVENESS OF FIRST-LINE TUMOR NECROSIS FACTOR INHIBITORS IN AXIAL SPONDYLOARTHRITIS; RESULTS FROM FIFTEEN COUNTRIES IN THE EuroSpA RESEARCH COLLABORATION NETWORK
46. OP0144 SLE-T2T – A DIGITAL TREAT-TO-TARGET CLINICAL DECISION SUPPORT SYSTEM FOR THE MANAGEMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS: DEVELOPMENT AND USABILITY EVALUATION
47. AB0425 WHAT DOES IT MEAN TO BE A DUAL BICLA AND SRI(4) RESPONDER? A POOLED ANALYSIS OF TWO PHASE 3 TRIALS IN PATIENTS WITH SLE
48. POS0693 IMPACT OF UPADACITINIB VERSUS ABATACEPT ON INDIVIDUAL DISEASE OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSES TO BIOLOGIC DMARDS
49. Economic considerations and patientsʼ preferences affect treatment selection for patients with rheumatoid arthritis: a discrete choice experiment among European rheumatologists
50. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.